EIM
VTVT icon

Essex Investment Management’s vTv Therapeutics VTVT Stock Holding History

Essex Investment Management’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-994
Closed -$198K – 380
2017
Q2 		$198K Hold
994
– – 0.03% 306
2017
Q1 		$261K Buy
+994
New +$227K 0.04% 306

Other funds holding VTVT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Essex Investment Management's VTVT Position: Q3 2017 in Review

Essex Investment Management sold out of vTv Therapeutics (VTVT) in Q3 2017, closing a stake of 994 shares — an estimated $198K sold.

Essex Investment Management first reported a position in VTVT in Q1 2017 and held it in 2 quarters. The position peaked at $261K in Q1 2017. 37 funds tracked by Wall St. Rank hold VTVT as of Q3 2017.

  • Essex Investment Management reported no remaining vTv Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Essex Investment Management sold 994 vTv Therapeutics shares in Q3 2017, an estimated $198K.
  • Essex Investment Management first reported a position in vTv Therapeutics in Q1 2017 and held it in 2 quarters.
  • Essex Investment Management's vTv Therapeutics position peaked at $261K in Q1 2017.
  • 37 funds tracked by Wall St. Rank held vTv Therapeutics as of Q3 2017.

Based on Essex Investment Management's 13F filing for Q3 2017, filed 30 Oct 2017.